Becton Dickinson

Track record: long dividend growth streak, opportunistic buybacks, and focused portfolio shaping. Strategic M&A has been meaningful: Edwards Critical Care (now APM) adds attractive monitoring and analytics; BD also divested lower-quality assets (e.g., surgical instrumentation in FY23) and is executing a tax-efficient RMT for Life Sciences.

Q3 FY25 reiterated the plan to complete the remaining 250 million dollars of a 1 billion dollar FY25 share repurchase, and BD has pledged at least half of the 4 billion dollar RMT cash distribution to buybacks with the remainder to reduce debt.

We view this as balanced and shareholder-minded while preserving investment in manufacturing capacity and innovation. Watch points: avoid overpaying in large deals, maintain discipline as margins expand.